SCHEMBL4706564

SCHEMBL4706564

CC(=O)c1c(-c2cccc(F)c2)nn(C(C)C)c(=O)c1Nc1ccccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ CSNK1E P49674 7/20 0.38
▸ CSNK1D P48730 6/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ ADRA1D P25100 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ ADRA1B P35368 1/20 0.38
▸ KDR P35968 2/20 0.37
▸ PIK3CD O00329 1/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ HCK P08631 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3CB P42338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707333 0.91 PDE4B (0.46) RAB9AKMT2APDE4BHTR1AADRA1D
SCHEMBL4706113 0.90 PDE4B (0.38) MEN1KMT2APDE4BCSNK1ECSNK1D
SCHEMBL4706058 0.84 PDE4B (0.56) RAB9AMEN1NPC1GAAKMT2A
SCHEMBL4707163 0.84 PDE4B (0.48) RAB9ANPC1PDE4BHTR1AADRA1D
SCHEMBL4706642 0.83 PDE4B (0.46) RAB9AMEN1NPC1GAAKMT2A
SCHEMBL4708887 0.83 PDE4B (0.39) RAB9AMEN1NPC1KMT2APDE4B
SCHEMBL3033451 0.82 CSNK1E (0.45) PDE4BCSNK1ECSNK1DNLRP3CDK5
SCHEMBL4707884 0.82 PDE4B (0.45) KMT2APDE4BCSNK1ECSNK1DHTR1A
SCHEMBL4708502 0.81 KCNK3 (0.41) PDE4BCSNK1ECSNK1DKDRPIK3CD
SCHEMBL4706663 0.81 CSNK1E (0.41) PDE4BCSNK1ECSNK1DKDRPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 — — US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 — — US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B RAB9A 2162/4885MEN1 3745/4885NPC1 4438/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B RAB9A 2162/4885MEN1 3745/4885NPC1 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback